Alembic Pharma Reports 4% Revenue Growth in Q3 FY25; Net Profit at Rs.138 Crores
Varahi media.com online news,Mumbai,4th February, 2025: Alembic Pharmaceuticals Limited has announced its consolidated financial results for the third quarter of FY25, reporting a 4% year-on-
Varahi media.com online news,Mumbai,4th February, 2025: Alembic Pharmaceuticals Limited has announced its consolidated financial results for the third quarter of FY25, reporting a 4% year-on-year (YoY) increase in revenue, with net sales reaching ₹1,693 crores. Despite market challenges, the company maintained EBITDA growth of 1%, with a net profit of ₹138 crores.
Financial Highlights (Q3 FY25)
- Net Sales: ₹1,693 crores (4% YoY growth)
- EBITDA: ₹271 crores (1% YoY growth)
- EBITDA Margin: 16%
- Net Profit: ₹138 crores
Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited, stated, “While market headwinds affected the acute segment, our specialty business outperformed industry growth. We have enhanced automation and AI to improve field force efficiency, impacting short-term performance but positioning us for long-term growth. Our US business recorded significant volume growth, and Ex-US markets continued to expand. However, the API business remains under pricing pressure.”
Operational Performance
India Branded Business
- Grew 3% YoY to ₹614 crores.
- Animal Health Business surged 22%, driven by strong brand performance.
- Specialty Therapies registered 6% growth.
- Three new product launches contributed to performance.
International Business
- US Generics revenue increased 10% YoY to ₹521 crores.
- Two new launches in the US market during Q3 FY25.
- Ex-US International Generics also grew 10% YoY to ₹299 crores.
- Seven ANDA approvals received during the quarter, bringing cumulative approvals to 219.
API Business
- Reported ₹259 crores in revenue, down 10% YoY due to pricing pressures.
Revenue Summary
| Particulars | Q3 FY25 | Q3 FY24 | % Change | 9M FY25 | 9M FY24 | % Change |
|---|---|---|---|---|---|---|
| India | ₹614 Cr | ₹596 Cr | 3% | ₹1,795 Cr | ₹1,697 Cr | 6% |
| USA | ₹521 Cr | ₹474 Cr | 10% | ₹1,449 Cr | ₹1,308 Cr | 11% |
| Ex-US | ₹299 Cr | ₹272 Cr | 10% | ₹868 Cr | ₹790 Cr | 10% |
| API | ₹259 Cr | ₹289 Cr | (10%) | ₹791 Cr | ₹916 Cr | (14%) |
| Total Revenue | ₹1,693 Cr | ₹1,631 Cr | 4% | ₹4,902 Cr | ₹4,712 Cr | 4% |
Alembic Pharmaceuticals remains optimistic about its specialty segment growth and international expansion. The company continues to focus on automation, AI-driven execution, and new product launches, which are expected to drive its future performance.
About Author
